This site is intended for healthcare professionals

Corbevax gets DCGI (India) approval to prevent COVID 19.

Read time: 1 mins
Published:6th Jan 2022
Biological E. Limited (BE), one of the world’s largest vaccine manufacturers, has announced that its Corbevax, India’s first indigenously developed protein sub-unit vaccine against COVID-19, received the approval from the Drugs Controller General of India (DGCI).

Corbevax is a “recombinant protein sub-unit” vaccine, developed from the receptor binding domain (RBD) of the spike protein on the virus’s surface combined with Dynavax’s CpG 1018 adjuvant with alum, which helps the body build the immune response against the virus. The vaccine has been developed by Biological E. Limited in collaboration with Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) and Baylor College of Medicine (Baylor) in Houston, Texas.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.